BioCryst Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.6M
Doctors Paid
632
Transactions
3,142
2024 Total
$319,125
Payment Breakdown by Category
Research$12.8M (87.7%)
Consulting$1.0M (7.2%)
Travel$149,951 (1.0%)
Food & Beverage$38,795 (0.3%)
Royalty/License$6,894 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.8M | 1,060 | 87.7% |
| Consulting Fee | $1.0M | 453 | 7.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $331,717 | 62 | 2.3% |
| Honoraria | $205,950 | 87 | 1.4% |
| Travel and Lodging | $149,951 | 322 | 1.0% |
| Food and Beverage | $38,795 | 1,151 | 0.3% |
| Grant | $10,000 | 1 | 0.1% |
| Royalty or License | $6,894 | 3 | 0.0% |
| Education | $41.10 | 3 | 0.0% |
Payments by Type
Research
$12.8M
1,060 transactions
General
$1.8M
2,082 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema | $1.9M | 1 | 329 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with Hereditary Angioedema | $1.4M | 0 | 169 |
| A Phase 1, Randomized Double-Blind, Placebo-Controlled QT/QTc Study To Evaluate The Effects That Extra Doses of Berotralstat Administered At Steady State Have On Cardiac Repolarization in Healthy Subjects | $1.4M | 0 | 29 |
| A Phase 1, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of BCX9250 in healthy subjects | $1.1M | 0 | 3 |
| A Phase 1, Randomized, double-bline, placebo-controlled dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of sing and multiple doses of BCX9250 in healthy subjects | $852,914 | 0 | 4 |
| A Phase 1 Drug Interaction Study to Evaluate the Effects of BCX7353 on the Pharmacokinetics of Two Oral Contraceptives Desogesterel and Combo CC | $833,261 | 0 | 11 |
| An open-label study to evaluate the long-term safety of daily oral BCX7353 in subjects with Type I and II hereditary angioedema | $768,334 | 0 | 119 |
| A Phase 1, Drug-drug Interaction Study to Evaluate the Effect of Multiple-dose BCX9930 on Cytochrome P450 Enzyme Activity Using Probe Substrates and the Effect of a P-gp Inhibitor on the Single-dose Pharmacokinetics of BCX9930 in Healthy Subjects | $542,139 | 0 | 4 |
| A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLEDOSE, TWO-PERIOD, CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF BCX7353 FORMULATIONS FOR ACUTE TREATMENT OF HEREDITARY ANGIOEDEMA | $407,348 | 0 | 8 |
| A SINGLE SEQUENCE, OPEN-LABEL, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF BCX7353 ON CYTOCHROME P450 3A4, 2C9, 2C19 AND 2D6 ENZYME ACTIVITY USING PROBE SUBSTRATES IN HEALTHY SUBJECTS | $400,256 | 0 | 5 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema | $339,072 | 0 | 84 |
| A Phase 1 Study to Determine the Absorption, Metabolism, and Excretion of [14C]-BCX9930 Following a Single Oral Dose in Healthy Male Subjects | $330,518 | 0 | 8 |
| A Phase 3 Randomized Double-blind Placebo-controlled Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema | $319,287 | 0 | 49 |
| A Phase 1 Study drug interaction study to evaluate the effect of cyclosporine on the pharmacokinetics of berotralstat in healthy subjects | $293,619 | 0 | 9 |
| An Open-Label Study of the Pharmacokinetics of Single Oral Doses of BCX7353 in Subjects with Varying Degrees of Renal Function. | $280,893 | 0 | 14 |
| AN OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE ORALDOSES OF BCX7353 IN SUBJECTS WITH HEPATIC IMPAIRMENT | $217,272 | 0 | 6 |
| A Phase 3, randomized, open label, active-controlled study to evaluate the safety, pharmacokinetics and effectiveness of IV peramivir compared to oral oseltamivir in pediatric subjects with acute uncomplicated influenza | $196,092 | 0 | 61 |
| A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of BCX7353 in Subjects with Hepatic Impairment. | $187,215 | 0 | 5 |
| A Randomized Study to Evaluate the Relative Bioavailability of Multiple Formulations of BCX4161 (Avoralstat) Compared to the Reference Soft Gelatin Capsule | $156,737 | 0 | 3 |
| BCX7353-108 (HAE) | $112,210 | 0 | 5 |
| A Phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharmacokinetics and effectiveness of intravenous permavir in elderly subjects with acute uncomplicated influenza infections and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. | $111,830 | 0 | 31 |
| A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Subjects with Varying Degrees of Renal Impairment | $94,255 | 0 | 5 |
| A Phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharmacokinetics and effectiveness of intravenous permavir in elderly subjects with acute uncomplicated influenza infections and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications | $82,877 | 0 | 43 |
| A Phase 1 Study drug interaction study to evaluate the effect of cyclosporine on the pharmacokinetics of berotralstat in healthy subjects | $51,402 | 0 | 1 |
| Laboratory Services for Testing- the efficacy of proprietary Type 1 BMP receptor inhibitors in a mouse model of FOP | $50,043 | 0 | 2 |
| A phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharacokinetics and effectiveness of intravenous peramivir in elderly subjects with acute uncomplicated influenxa infection at higher risk for influenza complications. | $41,091 | 0 | 17 |
| BCX7353-302 (HAE) | $36,330 | 0 | 4 |
| A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angiodema. | $34,058 | 0 | 5 |
| A PHASE 1 OPEN-LABEL RANDOMIZED SINGLEDOSE TWO-PERIOD CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF BCX7353 FORMULATIONS FOR ACUTE TREATMENT OF HEREDITARY ANGIOEDEMA | $31,234 | 0 | 1 |
| A PHASE 1, OPEN-LABEL, TASTE ASSESSMENT OF BEROTRALSTAT LIQUID FORMULATIONS IN HAE SUBJECTS | $31,156 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 26
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Lukena Karkhanis, M.d, M.D | Allergy & Immunology | San Antonio, TX | $11.15 | $0 |
| Dr. Mark Murray, M.d, M.D | Specialist | Diberville, MS | $11.11 | $0 |
| Patrick Perin, Md, MD | Allergy & Immunology | Teaneck, NJ | $11.07 | $0 |
| Dr. Gurdev Judge, M.d, M.D | Allergy & Immunology | Cary, NC | $11.07 | $0 |
| Dr. Ivan Lee, M.d, M.D | Internal Medicine | Hayward, CA | $11.06 | $0 |
| Dr. Donald Dvorin, M.d, M.D | Allergy & Immunology | Philadelphia, PA | $11.03 | $0 |
| Dr. George Belecanech, M.d, M.D | Allergy & Immunology | Voorhees, NJ | $11.03 | $0 |
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. has made $14.6M in payments to 632 healthcare providers, recorded across 3,142 transactions in the CMS Open Payments database. In 2024, the company paid $319,125. The top product by payment volume is Orladeyo ($4.3M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Allergy & Immunology ($475,052 to 326 doctors).
Payment categories include: Food & Beverage ($38,795), Consulting ($1.0M), Research ($12.8M), Travel & Lodging ($149,951), Royalties ($6,894).
BioCryst Pharmaceuticals, Inc. is associated with 6 products in the CMS Open Payments database, including Orladeyo, ORLADEYO, and Rapivab.